|
|
||||||||
DIMER as a NOVEL SOURCE of SELECTIVITY in G-Protein Signaling: GGL-ing AT CONVENTION
Department of Pharmacology and
1 UNC Neuroscience Center and Lineberger Comprehensive Cancer Center, School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7365

Heterotrimeric G proteins relay information between cell surface receptors and effector molecules in diverse signaling pathways to mediate critical cellular processes in both physiologic and pathologic conditions. Multiple isoforms of each of the three G protein subunits yield enormous structural and functional diversity. G proteins are thus obvious molecular targets for the therapeutic manipulation of signaling pathways. Their ubiquity among a vast array of G proteincoupled receptor pathways, however, may at first seem to threaten the attractiveness of G proteins as drug targets for specific signaling processes; in order for G proteins to be effective targets, some degree of selectivity must be defined and exploited. Although a great deal has been determined about the functional selectivity of G
subunits, relatively little is known regarding Gß
selectivity. In this review, we discuss functional diversity among Gß
subunits in both receptor coupling and effector activation. The novel functions of Gß5, in complex with proteins of the GGL domaincontaining R7 subfamily of regulators of G protein signaling, are discussed in detail, with specific focus on the potential of the Gß5RGS9-2 pair as a therapeutic target in Parkinsons disease.
This article has been cited by other articles:
![]() |
E. A. Yost, S. M. Mervine, J. L. Sabo, T. R. Hynes, and C. H. Berlot Live Cell Analysis of G Protein beta5 Complex Formation, Function, and Targeting Mol. Pharmacol., October 1, 2007; 72(4): 812 - 825. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. E. Zeller and H. G. Dohlman Illuminating Gbeta5 Signaling Mol. Pharmacol., October 1, 2007; 72(4): 810 - 811. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-C. Twizere, J.-Y. Springael, M. Boxus, A. Burny, F. Dequiedt, J.-F. Dewulf, J. Duchateau, D. Portetelle, P. Urbain, C. V. Lint, et al. Human T-cell leukemia virus type-1 Tax oncoprotein regulates G-protein signaling Blood, February 1, 2007; 109(3): 1051 - 1060. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. W. Tedford and G. W. Zamponi Direct G Protein Modulation of Cav2 Calcium Channels Pharmacol. Rev., December 1, 2006; 58(4): 837 - 862. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Wells, J. Dingus, and J. D. Hildebrandt Role of the Chaperonin CCT/TRiC Complex in G Protein beta{gamma}-Dimer Assembly J. Biol. Chem., July 21, 2006; 281(29): 20221 - 20232. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Mervine, E. A. Yost, J. L. Sabo, T. R. Hynes, and C. H. Berlot Analysis of G Protein beta{gamma} Dimer Formation in Live Cells Using Multicolor Bimolecular Fluorescence Complementation Demonstrates Preferences of beta1 for Particular {gamma} Subunits Mol. Pharmacol., July 1, 2006; 70(1): 194 - 205. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. H. Song, J. J. Waataja, and K. A. Martemyanov Subcellular Targeting of RGS9-2 Is Controlled by Multiple Molecular Determinants on Its Membrane Anchor, R7BP J. Biol. Chem., June 2, 2006; 281(22): 15361 - 15369. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. Drenan, C. A. Doupnik, M. P. Boyle, L. J. Muglia, J. E. Huettner, M. E. Linder, and K. J. Blumer Palmitoylation regulates plasma membrane-nuclear shuttling of R7BP, a novel membrane anchor for the RGS7 family J. Cell Biol., May 23, 2005; 169(4): 623 - 633. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. A. Martemyanov, P. J. Yoo, N. P. Skiba, and V. Y. Arshavsky R7BP, a Novel Neuronal Protein Interacting with RGS Proteins of the R7 Family J. Biol. Chem., February 18, 2005; 280(7): 5133 - 5136. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ASPET Journals | Pharmacological Reviews | Drug Metabolism and Disposition |
| Molecular Interventions | Molecular Pharmacology | J Pharmacology and Exp Therapeutics |